Contact Us
Drug Search Results
More Filters [+]

Everolimus

Alternative Names: everolimus, afinitor, certican, zortress, rad001, rad 001, rad-001, xience v, afinitor disperz
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Everolimus is a targeted cancer drug that blocks cancer growth, its also known by its brand name Afinitor. You might have everolimus if you have advanced: breast cancer that is hormone receptor positive. neuroendocrine tumour (NET) of the stomach, bowel, lung or pancreas. kidney cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/everolimus)

Mechanisms of Action: mTOR Inhibitor,Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Tuberous Sclerosis | Angiomyolipoma | Breast Cancer | Carcinoid Tumor | Giant Cell Tumors | Lipoma | Neuroendocrine Tumors | Oncology Solid Tumor Unspecified | Pancreatic Cancer | Oncology Unspecified | Kidney Diseases | Kidney Transplant | Liver Transplant | Transplantation Unspecified | Renal Cell Carcinoma | Oncology Unspecified

Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Stomatitis | Respiratory Tract Infections | Angiomyolipoma | Lipoma | Asthenia | Diarrhea | Edema | Hyperlipidemia | Hypertension | Anemia | Leukopenia | Hypercholesterolemia | Kidney Transplant | Liver Transplant | Constipation

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: BeiGene

Clinical Description

Map of Global Clinical Trials for Everolimus

Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, China, Colombia, Czech Republic, France, Germany, Greece, Hungary, Italy, Japan, Korea, Mexico, Netherlands, Poland, Russia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Angiofibroma|Breast Cancer|Seizures|Tuberous Sclerosis

Phase 2: Astrocytoma|Bone Cancer|Brain Cancer|Glioblastoma|Glioma|Male Breast Cancer|Meningioma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Sarcoma, Ewing

Phase 1: Acute Lymphoid Leukemia|Adenocarcinoma|Colorectal Cancer|Healthy Volunteers|Kidney Cancer|Non-Small-Cell Lung Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Renal Cell Carcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SIMRISE

P3

Recruiting

Breast Cancer

2028-08-31

CONNECT TarGeT-A

P2

Recruiting

Glioblastoma|Brain Cancer|Astrocytoma|Glioma

2028-08-28

2021PI203

P2

Unknown Status

Meningioma

2028-05-01

PNOC021

P1

Recruiting

Glioma

2027-12-31

Recent News Events

Date

Type

Title

12/13/2024

News Article

 Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

12/10/2024

News Article

 Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

12/06/2024

News Article

 Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

12/02/2024

News Article

 Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions